AMA: Healthcare 2026 Lynxter on Bringing Silicone 3D Printing Into Regulated Medical Production

Why It Matters

The technology eliminates costly tooling for customized silicone devices, unlocking economically viable, patient‑specific solutions and accelerating additive manufacturing adoption in regulated healthcare.

Key Takeaways

• Lynxter’s dual‑head extrusion prints medical‑grade silicone with isotropic properties.
• Water‑soluble gel and functional powder support enable complex geometries.
• Partnerships with Paris Hospital and 3Deus streamline regulatory qualification.
• Patient‑specific devices like ostomy adapters become economically viable.

Pulse Analysis

Silicone has long been the material of choice for soft medical devices, yet its liquid nature and stringent regulatory requirements have kept it out of mainstream additive manufacturing. Traditional injection molding and casting demand expensive tooling, making low‑volume, customized production prohibitively costly. Lynxter’s decade‑long effort culminates in a material extrusion system that mimics the chemistry of injection molding while operating like a fused‑deposition printer, delivering biocompatible, chemically inert parts without compromising performance.

The core of Lynxter’s innovation lies in a dual micro‑dosing head that precisely combines silicone A and B components, triggering cross‑linking without heat. By allowing the reaction to progress across multiple layers, the printed parts exhibit uniform, isotropic mechanical properties—an essential criterion for clinical certification. Complementary support strategies, including a water‑soluble gel and a functional powder developed with 3Deus Dynamics, resolve overhang challenges and enable intricate lattice structures while preserving material integrity. The platform also supports surface texturing, filler integration, and embedded sensors, expanding its utility beyond prototyping to fully qualified medical‑device production.

The commercial implications are significant. With partnerships such as Paris Hospital’s PRIM3D platform and 3Deus Dynamics’ ISO 13485‑certified facility, Lynxter is establishing a clear regulatory pathway for point‑of‑care manufacturing. This opens markets for patient‑specific solutions—ostomy‑bag adapters, custom surgical trainers, and on‑demand tooling—where traditional methods are uneconomical. As major players like Stratasys introduce certified silicone printers, Lynxter’s early mover advantage positions it to capture a growing segment of the healthcare additive‑manufacturing ecosystem, driving both cost reductions and innovation in personalized medicine.